治疗后甲状腺毒症患者TSH正常化的预测因素。

IF 0.7 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM
Acta Endocrinologica-Bucharest Pub Date : 2024-04-01 Epub Date: 2025-01-18 DOI:10.4183/aeb.2024.193
C H Han, C H Yin, J S Chen, Y S Chen, C H Chu, W C Chuang, H C Hung
{"title":"治疗后甲状腺毒症患者TSH正常化的预测因素。","authors":"C H Han, C H Yin, J S Chen, Y S Chen, C H Chu, W C Chuang, H C Hung","doi":"10.4183/aeb.2024.193","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Understanding factors delaying recovery in thyrotoxicosis patients is crucial for optimizing treatment plan.</p><p><strong>Objective: </strong>This study aimed to identify predictive factors for the delayed thyroid function recovery in thyrotoxicosis patients.</p><p><strong>Design: </strong>The study is a retrospective review of medical records of adult thyrotoxicosis patients diagnosed at Kaohsiung Veterans General Hospital, Taiwan, from January 2014 to December 2021. The duration of follow-up for the main outcome was at least 18 months.</p><p><strong>Subjects and methods: </strong>Patients newly diagnosed with thyrotoxicosis who were age > 18 years old, had a TSH level <0.1 μIU/mL, received CBZ or PTU treatment, and demonstrated a subsequent TSH increase to above 0.4 μIU/mL, were included.</p><p><strong>Results: </strong>The study included 443 patients. The average time to achieve normalized TSH levels was 6.9 months. Key factors associated with delayed TSH normalization included higher body mass index (BMI) [odds ratio (OR) = 1.06, confidence interval (CI): 1.01-1.12], elevated serum free T4 levels (OR = 1.97; CI, 1.44-2.69), and treatment with propylthiouracil (OR = 2.66; CI, 1.33-5.32). In contrast, factors such as sex, age, season of diagnosis, and comorbidities did not significantly impact the rate of TSH normalization.</p><p><strong>Conclusion: </strong>The study highlights the importance of considering individual patient characteristics, such as BMI and initial free T4 levels, in thyrotoxicosis management. The findings suggest a potential preference for carbimazole over PTU in achieving faster TSH normalization. This research contributes to the understanding of thyrotoxicosis recovery and supports the need for personalized treatment approaches in clinical practice.</p>","PeriodicalId":50902,"journal":{"name":"Acta Endocrinologica-Bucharest","volume":"20 2","pages":"193-200"},"PeriodicalIF":0.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750220/pdf/","citationCount":"0","resultStr":"{\"title\":\"PREDICTORS OF TSH NORMALIZATION IN THYROTOXICOSIS PATIENTS AFTER TREATMENT.\",\"authors\":\"C H Han, C H Yin, J S Chen, Y S Chen, C H Chu, W C Chuang, H C Hung\",\"doi\":\"10.4183/aeb.2024.193\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context: </strong>Understanding factors delaying recovery in thyrotoxicosis patients is crucial for optimizing treatment plan.</p><p><strong>Objective: </strong>This study aimed to identify predictive factors for the delayed thyroid function recovery in thyrotoxicosis patients.</p><p><strong>Design: </strong>The study is a retrospective review of medical records of adult thyrotoxicosis patients diagnosed at Kaohsiung Veterans General Hospital, Taiwan, from January 2014 to December 2021. The duration of follow-up for the main outcome was at least 18 months.</p><p><strong>Subjects and methods: </strong>Patients newly diagnosed with thyrotoxicosis who were age > 18 years old, had a TSH level <0.1 μIU/mL, received CBZ or PTU treatment, and demonstrated a subsequent TSH increase to above 0.4 μIU/mL, were included.</p><p><strong>Results: </strong>The study included 443 patients. The average time to achieve normalized TSH levels was 6.9 months. Key factors associated with delayed TSH normalization included higher body mass index (BMI) [odds ratio (OR) = 1.06, confidence interval (CI): 1.01-1.12], elevated serum free T4 levels (OR = 1.97; CI, 1.44-2.69), and treatment with propylthiouracil (OR = 2.66; CI, 1.33-5.32). In contrast, factors such as sex, age, season of diagnosis, and comorbidities did not significantly impact the rate of TSH normalization.</p><p><strong>Conclusion: </strong>The study highlights the importance of considering individual patient characteristics, such as BMI and initial free T4 levels, in thyrotoxicosis management. The findings suggest a potential preference for carbimazole over PTU in achieving faster TSH normalization. This research contributes to the understanding of thyrotoxicosis recovery and supports the need for personalized treatment approaches in clinical practice.</p>\",\"PeriodicalId\":50902,\"journal\":{\"name\":\"Acta Endocrinologica-Bucharest\",\"volume\":\"20 2\",\"pages\":\"193-200\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750220/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Endocrinologica-Bucharest\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4183/aeb.2024.193\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Endocrinologica-Bucharest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4183/aeb.2024.193","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:了解甲状腺毒症患者延迟康复的因素对优化治疗方案至关重要。目的:探讨甲状腺毒症患者甲状腺功能恢复迟缓的预测因素。设计:本研究回顾性分析2014年1月至2021年12月在台湾高雄退伍军人总医院诊断的成人甲状腺毒症患者的医疗记录。主要结果的随访时间至少为18个月。研究对象和方法:新诊断为甲状腺功能亢进症的患者,年龄在bb0 ~ 18岁,TSH水平。达到正常TSH水平的平均时间为6.9个月。与TSH正常化延迟相关的关键因素包括较高的身体质量指数(BMI)[优势比(OR) = 1.06,可信区间(CI): 1.01-1.12]、血清游离T4水平升高(OR = 1.97;CI, 1.44-2.69),丙基硫脲嘧啶治疗组(OR = 2.66;CI, 1.33 - -5.32)。相比之下,性别、年龄、诊断季节和合并症等因素对TSH正常化率没有显著影响。结论:该研究强调了在甲状腺毒症管理中考虑个体患者特征(如BMI和初始游离T4水平)的重要性。研究结果表明,在实现更快的TSH正常化方面,卡咪唑可能比PTU更有优势。这项研究有助于了解甲状腺毒症的恢复,并支持在临床实践中需要个性化的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
PREDICTORS OF TSH NORMALIZATION IN THYROTOXICOSIS PATIENTS AFTER TREATMENT.

Context: Understanding factors delaying recovery in thyrotoxicosis patients is crucial for optimizing treatment plan.

Objective: This study aimed to identify predictive factors for the delayed thyroid function recovery in thyrotoxicosis patients.

Design: The study is a retrospective review of medical records of adult thyrotoxicosis patients diagnosed at Kaohsiung Veterans General Hospital, Taiwan, from January 2014 to December 2021. The duration of follow-up for the main outcome was at least 18 months.

Subjects and methods: Patients newly diagnosed with thyrotoxicosis who were age > 18 years old, had a TSH level <0.1 μIU/mL, received CBZ or PTU treatment, and demonstrated a subsequent TSH increase to above 0.4 μIU/mL, were included.

Results: The study included 443 patients. The average time to achieve normalized TSH levels was 6.9 months. Key factors associated with delayed TSH normalization included higher body mass index (BMI) [odds ratio (OR) = 1.06, confidence interval (CI): 1.01-1.12], elevated serum free T4 levels (OR = 1.97; CI, 1.44-2.69), and treatment with propylthiouracil (OR = 2.66; CI, 1.33-5.32). In contrast, factors such as sex, age, season of diagnosis, and comorbidities did not significantly impact the rate of TSH normalization.

Conclusion: The study highlights the importance of considering individual patient characteristics, such as BMI and initial free T4 levels, in thyrotoxicosis management. The findings suggest a potential preference for carbimazole over PTU in achieving faster TSH normalization. This research contributes to the understanding of thyrotoxicosis recovery and supports the need for personalized treatment approaches in clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Endocrinologica-Bucharest
Acta Endocrinologica-Bucharest 医学-内分泌学与代谢
CiteScore
1.30
自引率
20.00%
发文量
53
审稿时长
6-12 weeks
期刊介绍: Acta Endocrinologica (Buc) is an international journal covering the fields of basic and clinical Endocrinology, Neuroendocrinology, Reproductive Medicine, Chronobiology, Human Ethology published quarterly Acta Endocrinologica (Buc) is the official international journal of the Romanian Society for Endocrinology. It continues the former Romanian Journal of Endocrinology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信